StreetAlpha
13F holdings · Q3 2026

Acorn Capital Advisors

New York, NY · files as Acorn Capital Advisors, LLC
Know the moment Acorn Capital Advisors filesYou follow Acorn Capital Advisors An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 2054410

Acorn Capital Advisors reported 22 stocks worth $364M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are CGON (22.0%), URGN (18.4%) and PBYI (11.3%). Compared with Q2 2026, the fund opened new positions in ANTX and ANNX, added to BCAX, ENGN and AURA and trimmed URGN, WHWK and KPTI.

Latest filing: what Acorn Capital Advisors did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
2 new5 added3 trimmed0 sold outBought about $20.4M · sold about $2.2M
New 2
Added 5
  • ENGN+$5.1M+200%
  • LONA+$1.8M+80%
  • Vyne Therapeutics +$689K+2146%
  • AURA+$605K+10%
  • BCAX+$465K+4%
Trimmed 3
Sold out 0

None

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$364M−0.7% vs last quarter
Stocks held222 new · 0 sold out
Top 5 weight70.2%very concentrated
Turnover6%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
CGON
CG Oncology Inc
$80.2M22.0%1.1MNo change8 of 8
2
URGN
Urogen Pharma Ltd
$67M18.4%1.6M−25K (−1%)8 of 8
3
PBYI
Puma Biotechnology Inc
$41M11.3%4.1MNo change8 of 8
4
CADL
Candel Therapeutics Inc
$36.5M10.0%3.5MNo change8 of 8
5
TRVI
Trevi Therapeutics Inc
$30.7M8.4%2.1MNo change8 of 8
6
CYBIN INC
$18.9M5.2%1.5MNo change8 of 8
7
JBIO
Jade Biosciences Inc
$13.9M3.8%987KNo change3 of 8
8
BCAX
Bicara Therapeutics Inc
$12.4M3.4%668K+25K (+4%)8 of 8
9
VSTM
Verastem Inc
$11.8M3.3%1.5MNo change8 of 8
10
OKUR
Onkure Therapeutics Inc
$7.8M2.1%2.8MNo change8 of 8
🔒 12 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Reported value

last 8 quarters
$186MQ4 '24
$150MQ1 '25
$153MQ2 '25
$197MQ3 '25
$295MQ4 '25
$352MQ1 '26
$366MQ2 '26
$364MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Acorn Capital Advisors 13F FAQ

What does Acorn Capital Advisors own?

Acorn Capital Advisors reported 22 stocks worth $364M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are CGON (22.0%), URGN (18.4%) and PBYI (11.3%). The table above lists every position in the filing (the top 10 without an account).

What did Acorn Capital Advisors buy and sell in Q3 2026?

Compared with Q2 2026: 2 new positions, 5 added to, 3 trimmed and 0 sold out. New positions include ANTX and ANNX.

When will Acorn Capital Advisors file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Acorn Capital Advisors's portfolio worth?

The Q3 2026 filing reports $364M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.